Brokerages predict that Humana Inc (NYSE:HUM) will report earnings per share (EPS) of $4.29 for the current quarter, according to Zacks. Seven analysts have issued estimates for Humana’s earnings. The lowest EPS estimate is $3.92 and the highest is $4.42. Humana posted earnings per share of $3.39 in the same quarter last year, which suggests a positive year-over-year growth rate of 26.5%. The company is scheduled to announce its next quarterly earnings report before the market opens on Wednesday, November 7th.
According to Zacks, analysts expect that Humana will report full-year earnings of $14.18 per share for the current fiscal year, with EPS estimates ranging from $14.14 to $14.25. For the next year, analysts expect that the company will post earnings of $17.33 per share, with EPS estimates ranging from $16.92 to $18.09. Zacks’ EPS averages are a mean average based on a survey of analysts that that provide coverage for Humana.
Humana (NYSE:HUM) last announced its earnings results on Wednesday, August 1st. The insurance provider reported $3.96 earnings per share for the quarter, topping the consensus estimate of $3.79 by $0.17. Humana had a net margin of 2.48% and a return on equity of 17.43%. The business had revenue of $14.26 billion during the quarter, compared to the consensus estimate of $14.16 billion. During the same quarter in the prior year, the firm earned $3.49 earnings per share.
HUM has been the subject of several recent research reports. BMO Capital Markets increased their target price on shares of Humana from $328.00 to $355.00 and gave the stock an “outperform” rating in a research note on Monday, June 25th. ValuEngine upgraded shares of Humana from a “hold” rating to a “buy” rating in a research note on Wednesday, July 4th. Piper Jaffray Companies increased their target price on shares of Humana from $326.00 to $350.00 and gave the stock an “overweight” rating in a research note on Friday, July 6th. Morgan Stanley initiated coverage on shares of Humana in a research note on Thursday, July 12th. They set an “overweight” rating and a $362.00 target price for the company. Finally, Royal Bank of Canada reiterated a “hold” rating and set a $318.00 target price on shares of Humana in a research note on Thursday, August 2nd. Seven equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $339.79.
In related news, CEO Bruce D. Broussard sold 18,000 shares of the firm’s stock in a transaction dated Monday, September 10th. The shares were sold at an average price of $328.66, for a total value of $5,915,880.00. Following the completion of the sale, the chief executive officer now owns 71,085 shares in the company, valued at $23,362,796.10. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Elizabeth D. Bierbower sold 3,092 shares of Humana stock in a transaction that occurred on Thursday, August 16th. The shares were sold at an average price of $330.00, for a total transaction of $1,020,360.00. Following the sale, the insider now owns 14,289 shares of the company’s stock, valued at $4,715,370. The disclosure for this sale can be found here. In the last 90 days, insiders sold 40,284 shares of company stock valued at $13,147,715. 0.60% of the stock is owned by insiders.
Several hedge funds have recently bought and sold shares of HUM. Sun Life Financial INC lifted its position in shares of Humana by 120.7% during the 2nd quarter. Sun Life Financial INC now owns 373 shares of the insurance provider’s stock valued at $111,000 after acquiring an additional 204 shares during the period. Financial Gravity Wealth Inc. acquired a new stake in shares of Humana during the 1st quarter valued at approximately $113,000. Migdal Insurance & Financial Holdings Ltd. lifted its position in shares of Humana by 2,984.6% during the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 401 shares of the insurance provider’s stock valued at $119,000 after acquiring an additional 388 shares during the period. Summit Trail Advisors LLC lifted its position in shares of Humana by 24,611.8% during the 1st quarter. Summit Trail Advisors LLC now owns 184,103 shares of the insurance provider’s stock valued at $184,000 after acquiring an additional 183,358 shares during the period. Finally, NuWave Investment Management LLC acquired a new stake in shares of Humana during the 2nd quarter valued at approximately $198,000. Institutional investors own 92.99% of the company’s stock.
Shares of HUM traded down $1.73 during mid-day trading on Monday, hitting $326.65. 650,086 shares of the company’s stock were exchanged, compared to its average volume of 748,773. Humana has a fifty-two week low of $231.90 and a fifty-two week high of $341.30. The company has a market capitalization of $45.24 billion, a price-to-earnings ratio of 27.89, a price-to-earnings-growth ratio of 1.64 and a beta of 0.97. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.43 and a current ratio of 1.43.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 26th. Investors of record on Friday, September 28th will be given a $0.50 dividend. The ex-dividend date is Thursday, September 27th. This represents a $2.00 dividend on an annualized basis and a yield of 0.61%. Humana’s payout ratio is currently 17.08%.
Humana Company Profile
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company operates through four segments: Retail; Group and Specialty; Healthcare Services; and Individual Commercial. The Retail segment offers Medicare and supplemental benefit plans to individuals or through group accounts.
Further Reading: Cash Flow
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.